Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02591615
Title Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Alliance Foundation Trials, LLC.
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Carboplatin + Paclitaxel

Carboplatin + Pemetrexed Disodium

Age Groups: adult
Covered Countries USA


No variant requirements are available.